News
Copyright: © 2019 Elsevier Ltd. All rights reserved.
Objective To evaluate the efficacy and safety of the Janus kinase-1-preferential inhibitor filgotinib versus placebo or tumour necrosis factor-α inhibitor therapy in patients with active rheumatoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results